6841.TWO Ever Fortune.AI Co. Ltd.
- Market cap
- TWD 4.59B
- P/E
- 71.4x
- P/B
- 3.08x
- ROE
- 1.6%
- Dividend yield
- 2.08%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6841.TWO undervalued?
Graham numberThe Graham number of Ever Fortune.AI Co. Ltd. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ever Fortune.AI Co. Ltd. fundamental analysis
No fundamental analysis for Ever Fortune.AI Co. Ltd. yet.
Ever Fortune.AI Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ever Fortune.AI Co. Ltd.
Ever Fortune.AI Co., Ltd., an cloud-based biomedical platform, provides medical artificial intelligence (AI) solutions and services in China. The company offers medical AI solutions, such as oncology radiotherapy, emergency radiology, computer assisted detection platform for bone scintigraphy, cardio suite SPECT myocardial perfusion agile workflows; and cloud medical, genetic testing AI analysis, smart health check-up scheduling, haircare AI cloud, and underwriting claims me…
Full company profileEver Fortune.AI Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ever Fortune.AI Co. Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 3.49M | 38.2M | 53.9M | 94.0M | 338M | 379M | 334M |
| Gross Profit | - | 3.01M | 30.5M | 38.9M | 46.6M | 208M | 225M | 244M |
| Operating Income | -50.0M | -67.7M | -67.7M | 137M | -45.1M | 30.5M | 38.6M | 52.4M |
| EBITDA | -50.0M | -57.1M | -54.9M | 155M | -16.9M | 78.0M | 148M | 82.2M |
| Net Income | - | -54.1M | -54.2M | 136M | -42.0M | 30.3M | 83.4M | 24.8M |
| EPS | - | -0.98 | -0.61 | 1.54 | -0.44 | 0.31 | 0.88 | 0.26 |
| Balance Sheet | ||||||||
| Total Assets | - | 1.61B | 1.55B | 1.68B | 2.09B | 2.09B | 2.12B | 2.88B |
| Total Liabilities | - | 29.4M | 39.0M | 33.7M | 88.0M | 148M | 111M | 571M |
| Shareholders' Equity | - | 1.58B | 1.51B | 1.65B | 1.93B | 1.87B | 1.68B | 1.58B |
| Cash & Short-term Investments | - | 1.52B | 1.27B | 1.20B | 1.41B | 81.8M | 538M | 975M |
| Total Debt | - | 2.93M | 3.15M | 2.98M | 2.56M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | - | -39.2M | -41.9M | -60.4M | -27.6M | 62.5M | 46.8M | -26.3M |
| Capital Expenditure | - | 7.76M | 31.2M | 7.78M | 19.0M | 49.5M | 76.9M | 57.3M |
| Free Cash Flow | - | -46.9M | -73.1M | -68.2M | -46.6M | 13.0M | -30.2M | -83.6M |
| Ratios | ||||||||
| ROE | - | -3.4% | -3.6% | 8.3% | -2.2% | 1.6% | 5.0% | 1.6% |
| ROA | - | -3.4% | -3.5% | 8.1% | -2.0% | 1.5% | 3.9% | 0.9% |
| Net Profit Margin | - | -1,552.9% | -141.7% | 253.2% | -44.7% | 9.0% | 22.0% | 7.4% |
| Debt to Equity | - | 0.00x | 0.00x | 0.00x | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ever Fortune.AI Co. Ltd. dividends
- Dividend yield
- 2.08%
- Forward dividend
- 1.00 TWD
- Payout ratio
- 114.7%
- Ex-dividend date
- May 19, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 95.6M | 1.01 | 114.7% |
| 2024 | TWD 96.4M | 1.00 | 318.0% |
| 2023 | TWD 194M | 2.03 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Ever Fortune.AI Co. Ltd.
- Insiders 33.86%
- Institutions 0.18%
- Public & others 65.96%
- Shares outstanding 94.5M
- Free float 63.7M
Ever Fortune.AI Co. Ltd. company profile
- Company name
- Ever Fortune.AI Co. Ltd.
- Ticker
- 6841.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Information Services
- Fiscal year end
- December
- Address
- No.360, Jingmao Rd, Taichung, Taiwan, 406040
- Phone
- 886 4 2321 3838
- Website
- everfortuneai.com.tw
About Ever Fortune.AI Co. Ltd.
Ever Fortune.AI Co., Ltd., an cloud-based biomedical platform, provides medical artificial intelligence (AI) solutions and services in China. The company offers medical AI solutions, such as oncology radiotherapy, emergency radiology, computer assisted detection platform for bone scintigraphy, cardio suite SPECT myocardial perfusion agile workflows; and cloud medical, genetic testing AI analysis, smart health check-up scheduling, haircare AI cloud, and underwriting claims medical image recognition platform. It also provides Biotech and Beauty solutions including renexo miracle skin essence, hair revitalizing essence. Ever Fortune.AI Co., Ltd. was founded in 1998 and is based in Taichung, Taiwan. Ever Fortune.AI Co., Ltd. operates as a subsidiary of An Ji Biomedical Corporation.
Ever Fortune.AI Co. Ltd. management
4- Dr. Ti-Hao WangCTO and Director of Research & Development
- Dr. Yu-Cheng LiManager
- En-De LiaoDirector of Marketing & Business
- Donald LinChief Information Security Officer - Division of Platform & Business